Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice

Behavioural Pharmacology

Volumn 19, Issue 5-6, 2008, Pages 518-529

  Nordquist, Rebecca E ^a   Savignac, Helene ^a   Pauly Evers, Meike ^a   Walker, Gaby ^a   Knoflach, Fred ^a   Borroni, Edilio ^a   Glaentzlin, Patricia ^a   Bohrmann, Bernd ^a   Messer, Jurg ^a   Ozmen, Laurence ^a   Albientz, Anita ^a   Spooren, Will ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Amphetamine; Dopamine; Dopamine receptor; Knockout; Locomotor activity; Neurokinin; Psychostimulant sensitization; Rotarod; Tachykinin; Tyrosine hydroxylase

Indexed keywords

AMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR AGONIST; QUINPIROLE; SENKTIDE; TYROSINE 3 MONOOXYGENASE; DOPAMINE; DRUG DERIVATIVE; PEPTIDE FRAGMENT; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; ELECTROPHYSIOLOGY; FEMALE; GENOTYPE; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; OLFACTORY BULB; PHENOTYPE; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; ROTAROD TEST; ANIMAL; ANIMAL BEHAVIOR; BODY EQUILIBRIUM; BRAIN; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PEPTIDE FRAGMENTS; POSTURAL BALANCE; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, NEUROKININ-3; SIGNAL TRANSDUCTION; SUBSTANCE P; TYROSINE 3-MONOOXYGENASE;

EID: 58149329141     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32830cd7f5     Document Type: Article

References (37)

1. Anderson J, Kuo S, Chase T, Engber T (1994). Dopamine D1 receptor-stimulated release of acetylcholine in rat striatum is mediated indirectly by activation of striatal neurokinin1 receptors. J Pharmacol Exp Ther 269:1144-1151.
2. Andersen MP, Pouzet B (2001). Effects of acute versus chronic treatment with typical or atypical antipsychotics on D-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology 156:291-304.
3. Bishop C, Walker PD (2004). Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat. Brain Res 1023:126-133.
4. Burt D, Creese I, Snyder S (1977). Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328.
5. Che FY, Vathy I, Fricker LD (2006). Quantitative peptidomics in mice: effect of cocaine treatment. J Mol Neurosci 28:265-275.
6. Deschamps K, Couture R (2005). The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation. Br J Pharmacol 145: 712-727.
7. Ding YQ, Shigemoto R, Takada M, Ohishi H, Nakanishi S, Mizuno N (1996). Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J Comp Neurol 364:290-310.
8. Florijn WJ, Tarazi FI, Creese I (1997). Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280:561-569.
9. Fowler SC, Zarcone TJ, Vorontsova E, Chen R (2002). Motor and associative deficits in D2 dopamine receptor knockout mice. Int J Dev Neurosci 20: 309-321.
10. Grace AA, Onn SP (1989). Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 9:3463-3481.
11. Huang N, Ase AR, Hebert C, Van Gelder NM, Reader TA (1997). Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 30:277-290.
12. Humpel C, Saria A, Regoli D (1991). Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism. Eur J Pharmacol 195:107-114.
13. Jacobson L, Cryan J (2007). Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav Genet 37: 171-213.
14. Jocham G, Lezoch K, Muller CP, Kart-Teke E, Huston JP, De Souza Silva MA (2006). Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core. Eur J Neurosci 24:1721-1732.
15. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period. Synapse 40:137-144.
16. Kemel M-L, Perez S, Godeheu G, Soubrie P, Glowinski J (2002). Facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after acute and chronic suppression of dopaminergic transmission in the matrix of the rat striatum. J Neurosci 22:1929-1936.
17. Lévesque M, Wallman MJ, Parent R, Sik A, Parent A (2006). Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci Res 57:362-371.
18. 3 receptor activation in the neonatal rat spinal cord in vitro. J Neurophysiol 86:2939-2950.
19. Marco N,Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, Steinberg R (1998). Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32:481-488.
20. Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN (1993). D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 45:195-200.
21. Meltzer H, Prus A (2006). NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov Today: Ther Strategies 3:555-560.
22. Meng Z-H, Feldpaush DL, Merchant KM (1998). Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. Mol Brain Res 61:39-50.
23. 2C receptors. Psychopharmacology (Berl) 156:58-62.
24. Nalivaiko E, Michaud JC, Soubrie P, Le Fur G, Feltz P (1997). Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience 78:745-757.
25. Nordquist RE, Delenclos M, Ballard TM, Savignac H, Pauly-Evers M, Ozmen L, Spooren W (2008). Cognitive performance in neurokinin 3 receptor knockout mice. Psychopharmacology 198:211-220.
26. Overton P, Elliott PJ, Hagan RM, Clark D (1992). Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat. Eur J Pharmacol 213:165-166.
27. Paxinos G, Watson C (1986). The rat brain in stereotaxic coordinates. 2nd ed. New York, USA: Academic Press.
28. Piazza PV, Calza L, Giardino L, Amato G (1990). Chronic thioridazine treatment differently affects DA receptors in striatum and in mesolimbo-cortical systems. Pharmacol Biochem Behav 35:937-942.
29. Seabrook GR, Bowery BJ, Hill RG (1995). Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. Eur J Pharmacol 273:113-119.
30. Siemiatkowski M, Maciejak P, Wislowska A, Zienowicz M, Sienkiewicz-Jarosz H, Szyndler J, et al. (2004). Neophobia and cortical and subcortical binding of the dopamine D2 receptor antagonist [3H]-raclopride. Life Sci 76:753-761.
31. Siuciak J, McCarthy S, Martin A, Chapin D, Stock J, Nadeau D, et al. (2007). Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits. Psychopharmacology 194:185-195.
32. Spooren W, Riemer C, Meltzer H (2005). NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 4:967-975.
33. Tremblay L, Kemel ML, Desban M, Gauchy C, Glowinski J (1992). Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2, and NK3 tachykinin receptors. Proc Natl Acad Sci USA 89:11214-11218.
34. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151:99-120.
35. Whitty CJ, Walker PD, Goebel DJ, Poosch MS, Bannon MJ (1995). Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience 64:419-425.
36. Whitty C, Paul M, Bannon M (1997). Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J Comp Neurol 382:394-400.
37. Wong JY, Clifford JJ, Massalas JS, Finkelstein DI, Horne MK, Waddington JL, Drago J (2003). Neurochemical changes in dopamine D1, D3 and D1/D3 receptor knockout mice. Eur J Pharmacol 472:39-47.